PainReform Ltd., a pharmaceutical company specializing in clinical stages, is dedicated to the development of therapies that provide an extended period of post-surgical pain relief in Israel. The company is headquartered in Tel Aviv, Israel.
| Revenue (TTM) | 17,000 |
| Gross Profit (TTM) | -53,000 |
| EBITDA | $-4.35M |
| Operating Margin | -16200.00% |
| Return on Equity | -90.40% |
| Return on Assets | -38.80% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $10.29 |
| Price-to-Book | 0.35 |
| Price-to-Sales (TTM) | 199.25 |
| EV/Revenue | 1.888 |
| EV/EBITDA | -2.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.50M |
| Float | 844,370 |
| % Insiders | 0.00% |
| % Institutions | 6.69% |
FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery with patient enrollment expected in the second half of 2026
Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch
TEL AVIV, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced that its DeepSolar business unit will participate in Energy Trading Week Europe 2026, taking place September 24–25, 2026, at the Business Design Centre in London.
New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch
Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch
Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential as a long-acting, single-administration post-operative analgesic Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential as a long-acting, single-administration post-operative analgesic
Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market decision-making Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market decision-making
Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile
Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRFX and any ticker you trade — then tracks every position and per-strategy win rate.
